Author

R. R. Amara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:rat· 3 Assay:bulk RNA-seq· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Sahoo· 2 shared A. Shiferaw· 2 shared G. D. Tomaras· 2 shared N. Cheedarla· 2 shared X. Shen· 2 shared A. A. Upadhyay· 1 shared A. B. Ward· 1 shared A. Chahroudi· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Sahoo

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions.

S. Dankwa, C. Kosman, M. Dennis, E. E. Giorgi, K. Vuong, I. Pahountis, A. Garza, J. McCarthy, B. T. Mayer, J. T. Ngo, C. A. Enemuo, D. G. Carnathan, S. Stanfield-Oakley, S. J. Berendam, C. Weinbaum, , R. Goswami

This study evaluates a triple bNAb combination in infant rhesus macaques, showing durable neutralization and effector functions with high predicted prevention efficacy against HIV strains.

PLOS ONE · Nov 11, 2024Peer-reviewedImmunology

Tailoring Tfh Profiles Enhances Antibody Persistence to a Clade C HIV-1 Vaccine in Rhesus Macaques

A. Verma, C. E. Hawes, S. R. Elizaldi, J. C. Smith, D. Rajasundaram, G. K. Pedersen, X. Shen, L. D. Williams, G. D. Tomaras, P. A. Kozlowski, R. R. Amara, S. S. Iyer

This study shows that inducing GC Tfh1 cells with MPLA+QS-21 adjuvant leads to higher and longer-lasting HIV-1 Env antibodies in rhesus macaques compared to CAF01.

bioRxiv · Jul 18, 2023 · PreprintImmunology

HIV, asymptomatic STI, and the rectal mucosal immune environment among young men who have sex with men

V. E. Van Doren, S. A. Smith, Y.-J. Hu, G. Tharp, S. Bosinger, C. G. Ackerley, P. M. Murray, R. R. Amara, P. K. Amancha, R. A. Arthur, H. R. Johnston, C. F. Kelley

This study examines the immunologic effects of HIV and asymptomatic bacterial STIs on the rectal mucosa in YMSM, finding HIV alters cellular composition while STIs increase pathogenic bacteria and inflammation in HIV-positive individuals.

PLOS Pathogens · May 30, 2023Peer-reviewedImmunology

TREM2+ and interstitial macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques

A. A. Upadhyay, T. N. Hoang, M. Pino, A. K. Boddapati, E. G. Viox, M. Y. H. Lee, J. Corry, Z. Strongin, D. A. Cowan, E. N. Beagle, T. R. Horton, S. Hamilton, H. Aoued, J. L. Harper, K. Nguyen, , S. E. Bosinger

This study identifies two macrophage populations driving inflammation in the lower airway during SARS-CoV-2 infection in rhesus macaques and shows baricitinib effectively reduces their influx and cytokine production.

bioRxiv · Oct 5, 2021 · PreprintMicrobiology

Changes at V2 apex of HIV-1 Clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

A. Sahoo, E. A. Hodge, C. LaBranche, T. T. Styles, X. Shen, N. Cheedarla, A. Shiferaw, G. Ozorowski, W.-H. Lee, A. B. Ward, G. D. Tomaras, D. C. Montefiori, D. J. Irvine, K. K. Lee, R. R. Amara

bioRxiv · Jun 15, 2021 · PreprintImmunology

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

N. K. Routhu, S. Gangadhara, N. Cheedarla, A. Shiferaw, S. A. Rahman, A. Sahoo, P.-Y. Shi, V. D. Menachery, K. Floyd, S. Fischinger, C. Atyeo, G. Alter, M. S. Suthar, R. R. Amara

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

bioRxiv · Jun 27, 2020 · PreprintImmunology